Costs
The unit costs used in the analysis are presented in The majority of responding women in the spironolactone group (182/184, 99%) increased to two tablets of spironolactone at week 6. The ‘standard treatment’ approach, used in the base-case economic evaluation, gave rise to a mean total intervention resource use cost of £122.87 (SD £13.04) per participant in the spironolactone group (Estimates of mean change in resource use and cost (UK£ 2021/22) and mean utility and QALY gain by treatment group (based on available case data)*Assumes that if spironolactone is found effective it would be prescribed in primary care.CUA, cost-utility analysis; eGFR, estimated Glomerular Filtration Rate; GP, General Practitioner; HCP, healthcare professional; QALY, quality-adjusted life year.Using available case data, when intervention use was combined with other health resource use, the unadjusted mean incremental cost per participant was £126.35 (95% CI £112.88 to £139.82) for women receiving spironolactone compared with women receiving no active systemic treatment in the base-case (